CXCR4 in human osteosarcoma malignant progression. The response of osteosarcoma cell lines to the fully human CXCR4 antibody MDX1338

Osteosarcoma (OS) is the most frequent primary malignant tumour of bone and metastases occur in 30% of cases, the 5-year survival rate is 25–30%. Although pre- and post-operative chemotherapy has improved prognosis in osteosarcoma (OS), high toxicity and natural and acquired drug-resistance are the...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollino, Serena, Palmerini, Emanuela, Dozza, Barbara, Bientinesi, Elisa, Piccinni-Leopardi, Martina, Lucarelli, Enrico, Righi, Alberto, Benassi, Maria Serena, Pazzaglia, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543022/
https://www.ncbi.nlm.nih.gov/pubmed/31193811
http://dx.doi.org/10.1016/j.jbo.2019.100239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543022/
https://www.ncbi.nlm.nih.gov/pubmed/31193811
http://dx.doi.org/10.1016/j.jbo.2019.100239

Ejemplares similares